Injectable Drug Delivery Market Set to Witness Impressive CAGR of 8.3% and Reaching US$ 32.5 Billion Valuation by 2030 | Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S

Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site, which enhances the patient’s compliance to the drug. The Injectable delivery enhances the rapid absorption of drug from various sites such as subcutaneous, intravenous, and intramuscular. The injectable delivery increases the bioavailability of the drug at the systemic circulation, which offers availability of drug at intended site of action.

When it comes to ensuring that medications reach their intended target, injectable drug delivery is widely regarded as the gold standard. Rapid medication absorption can be achieved via injectable delivery at a variety of locations, including the intravenous, subcutaneous, and intramuscular. Injectable drug delivery improves systemic bioavailability, which means more drug is available at the site of action.

Injectable drug delivery is a growing sector of the pharmaceutical industry, with a 2017 valuation of US$15,939.0 mn and a projected CAGR of 8.3% from 2018 through 2025. (2018 – 2026).

Get Exclusive Sample PDF Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2768

Our Sample Report May Includes:

• 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
• 115+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Requests.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
• Includes Updated List of tables & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

The global injectable medication delivery market is projected to expand due to the rising incidence of chronic disorders like diabetes and allergy.

The expansion of the market is anticipated to be driven by the rising incidence of chronic disorders like diabetes and others. About 10.3% of men and 9.6% of women aged 25 and older in Europe had diabetes in November 2011, according to the World Health Organization (WHO). In a similar vein, 8.5% of persons aged 18 and up worldwide had diabetes in 2014, as reported by the World Health Organization (WHO) factsheet for 2018.

Over the projected period, the global injectable drug delivery market is anticipated to rise as a result of industry participants’ efforts to develop and release injectors. Such is the case with the release of BerliPen areo 3 by Berlin-Chemie in Germany in 2016. Type 1 and type 2 diabetics can choose from six different insulins to use with the BerliPen areo 3, a 300-unit insulin pen. Parallel to Mylan’s success with generic versions of its EpiPen and EpiPen Jr., Teva Pharmaceuticals got FDA approval for their version in August 2018. Teva Pharmaceuticals is the pioneering generic drug maker, having won FDA approval for their products.

However, the rise of the market could be slowed by the increasing frequency of product recalls. When standard stability testing on retained samples revealed the presence of visible particles in the syringes, Bracco Diagnostics Inc. issued a Class I recall of nine batches of Isovue Pre-Filled Power Injector Syringes in December 2012, as reported by the FDA. The Stellant CT Injection Systems are designed to work with these syringes (FDA)

Key Players

Companies like these dominate the global market for injectable medicine delivery Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, and Injex Pharma GmbH

Direct Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2768

The expansion of the market is anticipated to be boosted by the increasing rate of product approval and launch in North America.

Increased investment in R&D and new product launches by North American companies has given the area a commanding share of the worldwide injectable medication delivery industry. Bayer’s linked auto-injector (BETACONNECT) and mobile app (myBETAapp) for treating relapsing-remitting multiple sclerosis (RRMS) were approved by the FDA in 2017. The app provides patients with a record of their injections, which they may then share with their doctor or nurse. In a similar vein, Genentech reported in October 2018 that Xolair (omalizumab) had been approved by the FDA for use in single-dose prefilled syringes (PFS) for the treatment of allergic asthma and chronic idiopathic urticaria (CIU).

Market expansion is anticipated over the forecast period because to rising prevalence of serious conditions including allergy, diabetes, and cardiac arrest in the region. For example, in 2014, the prevalence of anaphylaxis in the United States was 1.6% among the general population, and the number of hospitalizations due to the condition is steadily rising in the same country.

The market for injectable drugs is likely to grow because more companies are making auto-injectors available to people with severe allergies. For instance, epinephrine purchasers can get discounts of up to US$300 on the branded version of EpiPen and up to US$25 on the approved generic version of EpiPen by using discount cards made available by Mylan N.V

Why Choose This Report:

→» A qualitative and quantitative market study based on segmentation that includes both economic and non-economic factors

→» Data on market value for each section and sub-segment

→» Indicates the region and market segment that is likely to expand the fastest and dominate the market.

→» The consumption of the product/service in each region is highlighted, as are the factors affecting the market within each region.

→» The competitive landscape includes the top players’ market rankings, as well as new service/product launches, collaborations, company expansions, and acquisitions made by the companies profiled in the last few years.

Request for Enquiry or Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2768

Table of Contents with Major Points:

Executive Summary

• Introduction
• Key Findings
• Recommendations
• Definitions and Assumptions

Executive Summary

Market Overview

• Definition of Injectable Drug Delivery Market
• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Trends and Developments

Key Insights

• Key Emerging Trends
• Key Developments Mergers and Acquisition
• New Product Launches and Collaboration
• Partnership and Joint Venture
• Latest Technological Advancements
• Insights on Regulatory Scenario
• Porters Five Forces Analysis

Qualitative Insights Impact of COVID-19 on Global Injectable Drug Delivery Market

• Supply Chain Challenges
• Steps taken by Government/Companies to overcome this impact
• Potential opportunities due to COVID-19 outbreak

Conclusion 

Appendix

• Data Sources
• Abbreviations
• Disclaimer

TOC Continued…!

Explore More Report:

Middle east and asia injectable drugs market

Special purpose needles market

Safety needles market

North america and europe dermal filler market

Veterinary orthopedic implants market

North america scar treatment market

Drug delivery device market 

Degenerative disc disease treatment market

Safety needles market

Intraosseous infusion devices market